CINCINNATI, Ohio, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc. (“AbVacc”) for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease (“MVD”).

The mission of AbVacc is to utilize structure-based design for development of next generation vaccines and immunotherapeutics for treatment of infectious and inflammatory diseases. Building upon 15 years of research under the parent company Integrated BioTherapeutics, AbVacc now has a vibrant pipeline of monoclonal antibodies and engineered vaccines in advanced preclinical with several candidate entering the clinical stage in the next few years. To accomplish its ambitious goals, AbVacc has public private funding strategy and partnered with various Government funding agencies, primarily National Institute of Allergy and Infectious Diseases (NIAID) and CARB-X as well as private funding sources such as Novo Holdings Repair Impact Fund. Further strategic partnerships include EliteImmune Corp., Scripps Research Institute, La Jolla Institute for Immunology, ViroVax, LLC, University of Texas Medical Branch, Johns Hopkins University, University of Rochester, University of Maryland, and Washington University.

ROCKVILLE, Md., Nov. 1, 2021- Integrated BioTherapeutics Inc. (IBT) and Integral Molecular have collaboratively engineered proteins for developing broadly protective vaccines for Ebola and related viruses. Development of this next-generation vaccine was enabled by the combined application of IBT discovered neutralizing Ebola antibodies and Integral Molecular’s GeneCanvas protein engineering platform to identify glycoprotein mutations that make the Ebola virus vulnerable to immune detection.

Integrated BioTherapeutics Inc. (IBT), a Maryland biotechnology company specializing in emerging infectious diseases, announced today the receipt of a contract valued at up to $16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Maryland, has been shown in preclinical studies to be protective against both Marburg and Ravn virus.

Today, the Novo Holdings REPAIR Impact Fund announced a EUR 7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France. This investment will allow the company to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.

LimmaTech receives an exclusive clinical development license from AbVacc for a multivalent, toxoid vaccine candidate to prevent infections caused by Staphylococcus aureus, the leading cause of antimicrobial resistance-related deaths in the U.S. and Europe. LimmaTech will initiate Phase 1 clinical development of the vaccine candidate in 2024 with an option to acquire full worldwide rights after the trial readout